Quantcast Abc And Cbs Give No Credit To Novartis
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

Abc And Cbs Give No Credit To Novartis

Posted on 05/14/2007 22:09:07 | Link | Post Comment
by Julia A. Seymour
Business & Media Institute




Evening broadcasts praise 'promising' drug for osteoporosis without naming the manufacturer.


Both ABC and CBS evening news programs praised a new drug that could save lives threatened by osteoporosis. But they didn’t say what company spent years and millions of dollars developing it.

ABC “World News” anchor Charles Gibson called it “promising news.”

“CBS Evening News” anchor Katie Couric agreed, saying the new drug “may be just what the doctor ordered” for the 10 million Americans living with the disease.

The wonder drug hailed by both “Evening News” and “World News with Charles Gibson” on May 2 is zoledronic acid.

It is sold under the brand names Reclast and Zometa. But neither CBS nor ABC mentioned the maker of the new treatment: Novartis Pharmaceuticals (NVS).

Novartis should have been given credit for the innovative new drug, since it likely cost them millions in research and development costs. The Pharmaceutical Research and Manufacturers of America estimates the cost of an approved new drug to be more than $800 million.

Zoledronic acid differs from other osteoporosis medications because it can be injected through an IV in about 15 minutes, and only has to be given once a year.

Both broadcasts cited a study of postmenopausal women that resulted in a 70-percent decline in spine fractures and a 41-percent decline in hip fractures.

“Experts say reducing fractures can save lives,” said “Evening News” medical correspondent Dr. Jon LaPook.

The study did find an irregular heartbeat to be a potential side effect, which both programs reported.

Ignoring pharmaceutical companies and development costs is common in media coverage of the industry. In fact, between Jan. 1 and Sept. 20, 2006, only 22 percent of network stories named the company that developed the drug in question and only 2 percent of stories included cost, according to a Business & Media Institute study.


Source: BusinessAndMedia.org



RELATED READING:
- "60 Minutes" Takes 13 Minutes to Attack Drug Companies
- Cancer Drug, but not Drug Company, Praised by Networks

____________________
Stock Quote or
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
Morpheus Trading - Thu Oct 02, 2008 08:58AM
NOTE: Please click on the charts below to enlarge them if [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.